Table 2.
Effect of Different Treatments on Renal Tissue CAT, GR, Tissue HO-1, Nrf2 and Mitochondrial Complex I Activity in the Studied Groups
| Control | Carboplatin | Carboplatin+ Candesartan | Carboplatin + CoQ10 | Carboplatin + CMC | Carboplatin + Candesartan+CoQ10 | F-value | df | |
|---|---|---|---|---|---|---|---|---|
| Tissue CAT (U/mg tissue) | 29.2±0.4 | 13.54±0.19 a | 20.3±0.3 b | 18.9±0.28 b | 12.21±0.18 | 25.1±0.38 bcd | 71.93 | 51 |
| Tissue GR (U/g tissue) | 849.3±12.9 | 441.2±7.3 a | 652.4±8.74 b | 569.8±8.5 b | 445.5±7.72 | 743.55±10.3 bcd | 267.04 | 51 |
| Tissue HO-1 (ng/mg protein) | 0.32±0.02 | 0.14±0.01a | 0.21±0.01 b | 0.19±0.01 b | 0.13±0.01 | 0.26±0.01 bcd | 94.01 | 51 |
| Tissue Nrf2 (x10-1 ng/mg protein) | 0.27±0.02 | 0.11±0.01a | 0.19±0.01 b | 0.18±0.01 b | 0.12±0.01 | 0.23±0.02 bcd | 81.4 | 51 |
| Mitochondrial complex I activity (nmol NADH/min/mg protein) | 92.4±2.5 | 34.12±1.23 a | 48.6±1.7 b | 59.32±1.9 b | 37.4±1.42 | 72.35±2.2 bcd | 111.9 | 51 |
a
Significant compared to the control group (p-value less than 0.05);
b
Significant compared to carboplatin group (p-value less than 0.05);
c
Significant compared to carboplatin + candesartan group (p-value less than 0.05);
d
Significant compared to carboplatin + CoQ10 group (p-value less than 0.05),